INSERM U848, Institut Gustave Roussy, Pavillon de Recherche 1, 39 rue Camille Desmoulins, F-94805 Villejuif, France.
Nat Rev Drug Discov. 2012 Feb 3;11(3):215-33. doi: 10.1038/nrd3626.
It has recently become clear that the tumour microenvironment, and in particular the immune system, has a crucial role in modulating tumour progression and response to therapy. Indicators of an ongoing immune response, such as the composition of the intratumoural immune infiltrate, as well as polymorphisms in genes encoding immune modulators, have been correlated with therapeutic outcome. Moreover, several anticancer agents--including classical chemotherapeutics and targeted compounds--stimulate tumour-specific immune responses either by inducing the immunogenic death of tumour cells or by engaging immune effector mechanisms. Here, we discuss the molecular and cellular circuitries whereby cytotoxic agents can activate the immune system against cancer, and their therapeutic implications.
最近已经清楚的是，肿瘤微环境，特别是免疫系统，在调节肿瘤进展和对治疗的反应方面起着关键作用。正在进行的免疫反应的指标，如肿瘤内免疫浸润的组成，以及编码免疫调节剂的基因中的多态性，已经与治疗结果相关。此外，几种抗癌药物，包括经典的化疗药物和靶向化合物，通过诱导肿瘤细胞的免疫原性死亡或通过激活免疫效应机制，刺激肿瘤特异性免疫反应。在这里，我们讨论了细胞毒性药物可以激活免疫系统对抗癌症的分子和细胞回路及其治疗意义。
